Our mission is to improve Europe-wide awareness, understanding, and access to diagnosis and treatment of inherited lipid conditions, (specifically FH, HoFH, Lp(a), FCS), so that all those impacted receive optimal treatment and support, resulting in longer and healthier lives.
Our vision is to achieve early recognition of life-threatening dyslipidaemias for all impacted people, in a future where:
So that together with our Network patient organizations and other stakeholders, we will be able to prevent the consequences (among them premature heart attacks and deaths) of inherited dyslipidaemias.
FH Europe Foundation (FHEF) has as its object the advancement of health - the prevention of early atherosclerotic cardiovascular diseases (ASCVD) and other diseases as a consequence of inherited dyslipidaemias, in particular through timely screening, diagnosis and treatment as well as education, health literacy promotion, access to treatment and related health policy influencing.
The FHEF foundation will specifically but not exclusively devote itself to the following activities:
To deliver on its mission, FHEF identified the following strategic projects:
Our impact report can be downloaded here
FH Europe has been registered as a foundation - Stichting FH Europe Foundation, in the Netherlands, KvK number 86407481, RSIN number 863956762, since May 17th, 2022. However it is not trading due to the pending ANBI status. Therefore, the finance and the impact reports shared on this website relate to current CIO.
Our latest financial report is available to download here
FH Europe has been registered as a foundation - Stichting FH Europe Foundation, in the Netherlands, KvK number 86407481, RSIN number 863956762, since May 17th, 2022. However it is not trading due to the pending ANBI status. Therefore, the finance and the impact reports shared on this website relate to current CIO.
Policy documents are available to download here